Therefore, these protein receptors are interconnected and have a cascade effect in overall pathology of COVID-19. It is hypothesized that combination of medications for VEGFA (Bevacizumab), IL6 (Tocilizumab), AKT1 (BAY 1125976), IGF1 (Increlex), etc. might be useful to manage the disease. Therefore, when SARS-CoV-2 binds to human ACE2 receptor, the above-mentioned protein receptors and their cascading interactions to other proteins will be affected. This interaction is further seen as pathology in human system.